Latest Shareholder Capital News

Otto Energy delivered a solid Q4 2024 with a 6% rise in production and a 4% increase in revenue, supported by operational improvements and disciplined cost management. The company also navigates a pending ATO ruling on a significant shareholder capital return.

Percheron Therapeutics has terminated its phase IIb avicursen trial for Duchenne muscular dystrophy after failing to meet efficacy endpoints, while securing $14.85 million in fresh capital to explore new therapeutic opportunities.

Tigers Realm Coal is finalising the sale of its Russian subsidiaries for US$49 million, pending crucial Presidential approval, while navigating recent leadership shifts.